PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Trade (domestic/foreign) TRD

Korea Free Trade Agreement: Provisions related to intellectual property, market access and public health Trans-Pacific Strategic Economic Partnership Agreement (TPP): Provisions related to intellectual property and innovation issues Issues related to Special 301 and National Trade Estimate (NTE) submissions Preference Programs International market access and intellectual property issues Biopharmaceutical innovation policy issues

Contacted: Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Executive Office of the President (EOP); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); White House Office; State, Dept of (DOS); Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

H.R. 243, Patent Lawsuit Reform Act of 2011: Provisions related to false patent marking H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 1056, Patent Continuing Disclosure Act: Provisions related to false patent marking H.R. 1249, America Invents Act: Provisions related to patent reform H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 2276, To require the Director of the United States Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes: gene patent study provisions S. 23, America Invents Act: Provisions related to patent reform S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics International intellectual property issues Biopharmaceutical innovation policy issues

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); SENATE; White House Office; Commerce, Dept of (DOC); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Internal Revenue Service (IRS)

Bills named: H.R. 741 (112th), H.R. 243 (112th), H.R. 2276 (112th), H.R. 2182 (112th), H.R. 1056 (112th), H.R. 1249 (112th), S. 373 (112th), S. 23 (112th), S. 27 (112th)

Medicare/Medicaid MMM

H.R. 452, Medicare Decisions Accountability Act of 2011: Provisions related to Independent Payment Advisory Board (IPAB) H.R. 675 Strengthening Medicare Anti-Fraud Measures Act of 2010: Provisions related to exclusion issues H.R. 999, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues H.R. 2190 Medicare Drug Savings Act of 2011: Provisions related to Part D issues H.R. 2248 Medicare Prescription Drug Price Negotiation Act of 2011: Provisions related to Part D non-interference issues S. 31, Prescription Drug and Health Improvement Act of 2011: Provisions related to Part D non-interference provisions S. 44, Medicare Prescription Drug Price Negotiation Act of 2011: Provisions related to Part D issues S. 365, Budget Control Act of 2011: Deficit reduction issues related to Medicare/Medicaid S. 454, Strengthening Program Integrity and Accountability in Health Care Act of 2011: Provisions related to exclusion issues S. 560, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues S. 668, Health Care Bureaucrats Elimination Act: Provisions related to Independent Payment Advisory Board (IPAB) S. 1206, Medicare Prescription Drug Savings Act of 2011: Provisions related to Part D issues S. 1251, Medicare and Medicaid FAST Act: Provisions related to Part D issues

Contacted: SENATE; U.S. Trade Representative (USTR); State, Dept of (DOS); White House Office; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Commerce, Dept of (DOC); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 999 (112th), S. 1251 (112th), S. 44 (112th), S. 31 (112th), S. 560 (112th), S. 454 (112th), S. 1206 (112th), H.R. 2190 (112th), H.R. 452 (112th), S. 668 (112th), S. 365 (112th), H.R. 2248 (112th), H.R. 675 (112th)

Budget/Appropriations BUD

H.R. 2017, Department of Homeland Security Appropriations Act, 2012: Provisions relating to Customs and Border Protection H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012: FDA related provisions H.R. 2608, Continuing Appropriations Act, 2012: FDA funding and related provisions S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012: HHS related provisions

Contacted: Commerce, Dept of (DOC); Executive Office of the President (EOP); State, Dept of (DOS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; U.S. Trade Representative (USTR); White House Office; Internal Revenue Service (IRS)

Bills named: H.R. 2608 (112th), H.R. 2112 (112th), H.R. 2017 (112th), S. 1599 (112th)

Health Issues HCR

H.R. 5, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011: Provisions related to FDA and product liability H.R. 1065, Pill Mill Crackdown Act of 2011: Provisions related to prescription drug abuse H.R. 1266, Fraudulent Prescription Prevention Act of 2011: Provisions related to prescription drug abuse H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 2119, Ryan Creedon Act of 2011: Provisions related to drug diversion H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011: Provisions related to prescription drug shortages S. 218, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011: Provisions related to FDA and product liability S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011: Provisions related to importation S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011: Provisions related to prescription drug abuse S. 2672, Preserving Access to Orphan Drugs Act of 2011: Provisions related to orphan drug definition and health reform fee Health care reform implementation issues, including health reform fee and essential benefits General FDA related advocacy Prescription Drug User Fee Reauthorization Anti-counterfeiting issues Biopharmaceutical innovation policy issues

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); State, Dept of (DOS); SENATE; Executive Office of the President (EOP); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; White House Office

Bills named: H.R. 2245 (112th), H.R. 1266 (112th), H.R. 1065 (112th), S. 296 (112th), H.R. 2119 (112th), S. 218 (112th), H.R. 2182 (112th), S. 507 (112th), S. 2672 (112th), S. 319 (112th), H.R. 5 (112th)